Good morning, degenerates. Strap in—here’s yesterday’s action and what you need to load up on before the bell.
Market Pulse: Tech’s melt-up kept momentum alive as Microsoft rode the Nvidia wave, lifting sentiment across the board.
Key Movers: Microsoft Stock Climbs Toward 515 Dollars as Nvidia Fueled Tech Rally Meets Fed Chair Warsh Speech (Ibtimes.com.au) and Gap Stock Soars More Than 13 Percent as Retailer Beats Earnings Estimates and Raises Full Year Outlook (Ibtimes.com.au) stole the spotlight.
Macro & Politics: Charles Schwab says Bitcoin short squeeze is over as leverage resets and Fed stays hawkish (Crypto Briefing), underlining lingering rate fears.
What’s Next: Eyes on SaaSpocalypse Is ‘Nonsense’ Says Salesforce CEO Amid Earnings Beat and Anthropic Partnership (Thedailyupside.com) as the Salesforce call could reset tech expectations.
Market Commentary
Everyone’s ignoring how the real fireworks might come from pharma. Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera (Financial Post) could reroute capital that’s currently chasing every AI riff. Meanwhile, the Nvidia-driven frenzy has traders glossing over these under-the-radar wins—hell, this is where unseen profits hide.
Here’s the twist: policy fights are pairing with product breakthroughs to shape markets. Other Barks & Bites for Friday, August 28… (IPWatchdog.com) details how the IRA Negotiation Program survives Big Pharma’s pushback, and the Patent Troll Showdown Heads to SCOTUS. When government and courtroom drama collide with innovation—watch out for sudden shifts in where capital flows.
If you want actionable insight, scout the turnaround plays and regulatory arbitrage. Gap’s execution story is no fluke, and Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit (The Times of India) could be a sleeper catalyst. Adjust your watch list—diversifying beyond the usual tech suspects might be the smartest move today.
📈 Breaking Financial News
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV). MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Red…
Charles Schwab says Bitcoin short squeeze is over as leverage resets and Fed stays hawkish
The Bitcoin market may face volatility as the short squeeze ends, with potential for a digestion phase amid a hawkish Federal Reserve stance. The post Charles Schwab says Bitcoin short squeeze is over as leverage resets and Fed stays hawkish appeared first on…
Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit
Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's…
Gap Stock Soars More Than 13 Percent as Retailer Beats Earnings Estimates and Raises Full Year Outlook
Gap Inc. shares rose over 13% following a Q2 earnings beat and the announcement of new leadership at Old Navy. Despite revenue decline, profitability exceeded expectations, boosting investor confidence.
Ulta Beauty Slips 4% Despite Raised Guidance and Q2 Earnings Beat, e.l.f. Beauty Pulls Back
Ulta Beauty posted a clean earnings beat and raised its full year outlook, yet traders punished the stock in heavy Friday volume. Understanding why requires…
White House Insider Buck Sexton: “Trump's Next Move Will Shock the World”
Dramatically increase U.S. power… and trigger a massive American market boom the likes of which we haven't seen in 75 years. Get the details here now.
🔍 Market Analysis & Insights
SaaSpocalypse Is ‘Nonsense’ Says Salesforce CEO Amid Earnings Beat and Anthropic Partnership
The company’s stock soared more than 20% Thursday after it beat expectations in its fiscal second-quarter earnings.
Avis Budget Group, Inc. Notice of September 29, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
NEW YORK and NEW ORLEANS, Aug. 28, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Avis Budget Group, Inc. (“Avis” or the “Company”) (NasdaqGS: CAR) of a cl…
ZEC Holds Strong at $790 Amid Institutional Bet on Zcash ETF, Analysts Predict Bigger Price Moves
According to the analyst, Zcash is preparing to move even higher, driven by its recent ETF launch and a rejuvenated crypto market rally.
Other Barks & Bites for Friday, August 28: CCIA Urges SCOTUS to Take Up ‘Patent Troll’ Case; Federal Circuit Transfers T-Mobile Contract Case to Fifth Circuit; and Another Drugmaker Challenge to IRA’s Negotiation Program Fails
This week in Other Barks & Bites: the Fifth Circuit nixes an appeal lodged by PhRMA and other drugmaker industry organizations against the Medicare drug negotiation program under the Inflation Reduction Act; the Ninth Circuit finds that Boeing’s patent invent…
Microsoft Stock Climbs Toward 515 Dollars as Nvidia Fueled Tech Rally Meets Fed Chair Warsh Speech
Microsoft's stock continues its upward trajectory, driven by strong AI growth and market optimism, despite volatility and Federal Reserve discussions on inflation and interest rates.
Don't Buy AI Stocks. George Gilder Says a $200 Billion Technology Could Make Data Centers Obsolete.
The man who called Apple, Netflix and Amazon early says wafer-scale processing is AI's biggest disruption — and just three companies control it. He calls them the Trillion Dollar Triangle.
💰 Investment Opportunities
Bitcoin Slips Below $80,000 After Kevin Warsh Inflation Vow
Bitcoin slipped back below $80,000 on Friday after Federal Reserve Chair Kevin Warsh pledged to bring inflation back to target, pushing short-term Treasury y…
Target takes big step to be more like Costco
As part of its turnaround, the company is focused on building trust and adding value.
Klarna Rallies 6%, Sezzle Gains 2% as Buy Now Pay Later Relief Trade Broadens, Affirm Jumps 10%
Stripe and Advent International just walked away from a potential $50 billion PayPal takeover, and the BNPL challengers are celebrating loudly. Here is what…
It’s Nvidia’s world. We just live in it
The artificial intelligence juggernaut kept cruising along this week thanks to big earnings results from Nvidia — and even Salesforce, the supposed epicenter of the SaaSpocalypse. Nvidia not only beat all expectations for revenue, CEO Jensen Huang (pictured) …
Best Buy Hikes Outlook After Hot Summer Quarter
Despite tariff chaos, soaring electronics prices, and deflating consumer sentiment, Best Buy just delivered a strong beat.
This $5 Stock's Patented Tech Powers SpaceX's Most Profitable Division
Satellite constellations are worthless unless the data gets to the ground fast. Ross Givens says one tiny firm solved that physics problem — and is the only company that can supply the component at commercial scale. His new report is free for now.